This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rauth, A. M. Articles by Tannock, I. F. Search for Related Content PubMed PubMed Citation Articles by Rauth, A. M. Articles by Tannock, I. F.

Activity of Mitomycin C for Aerobic and Hypoxic Cells in Vitro and in Vivo¹

Division of Physics [A. M. R., J. K. M., I. F. T.] and Department of Medicine [I. F. T.], Princess Margaret Hospital and Ontario Cancer Institute, and the Department of Medical Biophysics, University of Toronto [A. M. R., I. F. T.], 500 Sherbourne Street, Toronto, Ontario, Canada M4X 1K9

We have observed the selective toxicity of mitomycin C toward hypoxic as compared to aerobic cells in vitro for three established cell lines (Chinese hamster ovary, Chinese hamster V-79, and human HeLa) and for cells from the transplantable KHT murine tumor. The magnitude of the selective toxicity was cell line dependent.

We have studied the in vivo effects of mitomycin C against aerobic and hypoxic cells of two transplantable murine tumors: the KHT fibrosarcoma and the 16/C mammary carcinoma. Either mitomycin C was given with radiation to kill most of the aerobic cells, or it was given alone. Endpoints of response were cell survival assessed by lung colony assay for the KHT tumor, and growth delay for the 16/C tumor. In some experiments, mitomycin C appeared more effective when used with radiation than when used alone, but the results of combined treatment fell just within the range of additivity as defined by isobologram analysis. The effects of combined treatment were independent of the order in which drug and radiation were given.

Mitomycin C was also used in combination with Adriamycin to treat the 16/C tumor, since we have found previously that Adriamycin spares hypoxic cells in this tumor. In three of four experiments, combined drug effects were slightly greater than predicted by an additive relationship. We conclude that mitomycin C is active against hypoxic cells in two murine tumors, but that it has at most minor specificity for hypoxic as compared to aerobic cells in vivo.

¹ Supported by research grants from the National Cancer Institute of Canada, the Medical Research Council of Canada, and the Ontario Cancer Treatment and Research Foundation.

² To whom requests for reprints should be addressed.

Received 11/29/82. Accepted 6/ 9/83.

This article has been cited by other articles:

				M. Rastogi, M. Srivastava, K. S. Chufal, M. C. Pant, K. Srivastava, and M. B. Bhatt Mitomycin and Fluorouracil in Combination with Concomitant Radiotherapy: A Potentially Curable Approach for Locally Advanced Head and Neck Squamous Cell Carcinoma Jpn. J. Clin. Oncol., October 1, 2005; 35(10): 572 - 579. [Abstract] [Full Text] [PDF]

				H. A. Seow, P. G. Penketh, M. F. Belcourt, M. Tomasz, S. Rockwell, and A. C. Sartorelli Nuclear Overexpression of NAD(P)H:Quinone Oxidoreductase 1 in Chinese Hamster Ovary Cells Increases the Cytotoxicity of Mitomycin C under Aerobic and Hypoxic Conditions J. Biol. Chem., July 23, 2004; 279(30): 31606 - 31612. [Abstract] [Full Text] [PDF]

				O Pradier, K Eberlein, E Weiss, M C Jackel, and C F Hess Radiotherapy combined with simultaneous chemotherapy with mitomycin-C and 5-fluorouracil for inoperable head and neck cancer Br. J. Radiol., April 1, 2001; 74(880): 368 - 374. [Abstract] [Full Text] [PDF]

				J. M. Brown The Hypoxic Cell: A Target for Selective Cancer Therapy--Eighteenth Bruce F. Cain Memorial Award Lecture Cancer Res., December 1, 1999; 59(23): 5863 - 5870. [Abstract] [Full Text] [PDF]